Use of antibiotics is associated with worse clinical outcomes in patients with cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis

Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials

(2020) M. Chalabi et al.   ANNALS OF ONCOLOGY

Impact of antibiotic use and other concomitant medications on the efficacy of immune checkpoint inhibitors in patients with advanced cancer

(2020) A. Iglesias-Santamaría   Clinical & Translational Oncology

Impact of the gut microbiome on immune checkpoint inhibitor efficacy— a systematic review

(2020) J. Pierrard et al.   Current Oncology

Effect of baseline medications on response to immunotherapy in hepatocellular carcinoma.

(2020) Tomi Jun et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of antibiotic exposure on the efficacy of immune checkpoint blockade in MSI-H metastatic CRC.

(2020) Victoria Serpas et al.   JOURNAL OF CLINICAL ONCOLOGY

Antibiotic use in advanced non-small cell lung cancer (NSCLC) patients receiving immune checkpoint inhibitors across the Northern Ireland Cancer Network

(2020) C. Forde et al.   LUNG CANCER

Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer

(2020) MARTIN SVATON et al.   ANTICANCER RESEARCH

Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications

(2020) Daniel Spakowicz et al.   BMC CANCER

First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status

(2020) Francesco Facchinetti et al.   EUROPEAN JOURNAL OF CANCER

Association of antibiotic exposure with survival and toxicity in patients with melanoma receiving immunotherapy

(2020) Jahan J Mohiuddin et al.   JNCI-Journal of the National Cancer Institute

NSCLC Immunotherapy Efficacy and Antibiotic Use: A Systematic Review and Meta-Analysis

(2020) Lise Lurienne et al.   Journal of Thoracic Oncology

Survival of Patients Treated with Antibiotics and Immunotherapy for Cancer: A Systematic Review and Meta-Analysis

(2020) Fausto Petrelli et al.   Journal of Clinical Medicine

Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors

(2019) Arielle Elkrief et al.   OncoImmunology

Impact of concurrent medications on outcomes with PD1/PD-L1 inhibitors for metastatic urothelial carcinoma.

(2019) Archana Agarwal et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of antibiotic use on response to treatment with immune checkpoint inhibitors.

(2019) Uqba Khan et al.   JOURNAL OF CLINICAL ONCOLOGY

Results of an Italian CORE-IMMUNO study: Safety and clinical-related biomarkers as predictors of immunotherapy (IT) benefit in real-world treatment of various advanced tumors (ATs).

(2019) Cristina Masini et al.   JOURNAL OF CLINICAL ONCOLOGY

Association of medication (Med) and antibiotic (Abx) use with response and survival in advanced melanoma (MEL) receiving PD-1 inhibitors.

(2019) Amit Hemadri et al.   JOURNAL OF CLINICAL ONCOLOGY

The diversity of gut microbiome is associated with favorable responses to anti-PD-1 immunotherapy in Chinese non-small cell lung cancer patients

(2019) Yueping Jin et al.   Journal of Thoracic Oncology

Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer

(2019) Sha Zhao et al.   LUNG CANCER

Exploring the emerging role of the microbiome in cancer immunotherapy

(2019) Jessica Fessler et al.   Journal for ImmunoTherapy of Cancer

Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer

(2019) Giulia Galli et al.   LUNG CANCER

Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer

(2019) Nadina Tinsley et al.   ONCOLOGIST

Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small cell lung cancer patients treated with nivolumab

(2019) Julia Ouaknine Krief et al.   Journal for ImmunoTherapy of Cancer

Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade

(2019) Huemer et al.   Journal of Clinical Medicine

Neutrophil–to–lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors

(2019) JHE-CYUAN GUO et al.   ANTICANCER RESEARCH

Antibiotic use and the efficacy of immune checkpoint inhibitors in cancer patients: a pooled analysis of 2740 cancer patients

(2019) Xuan-Zhang Huang et al.   OncoImmunology

Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer

(2019) David J. Pinato et al.   JAMA Oncology

Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis

(2019) Hamzah Abu-Sbeih et al.   Journal for ImmunoTherapy of Cancer

The Impact of Antibiotics on Prognosis of Metastatic Renal Cell Carcinoma in Japanese Patients Treated With Immune Checkpoint Inhibitors

(2019) KOSUKE UEDA et al.   ANTICANCER RESEARCH

The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study

(2019) Hyunho Kim et al.   BMC CANCER

Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors

(2019) Anne Schett et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

PD1.05 Relevance of Antibiotic Use on Clinical Activity of Immune Checkpoint Inhibitors in Hispanic Patients with Advanced Non-small-cell Lung Cancer (CLICAP-ABs)

(2019) F. Barrón et al.   Journal of Thoracic Oncology

P2.04-69 Impact of Antibiotic Usage on Survival During Checkpoint Inhibitor Treatment of Non-Small Cell Lung Cancer (NSCLC)

(2019) C. Hogue et al.   Journal of Thoracic Oncology

P1.04-16 Early Antibiotic Use Affects the Efficacy of First Line Immunotherapy in Lung Cancer Patients but Route of Administration Seems to be Decisive

(2019) X. Mielgo Rubio et al.   Journal of Thoracic Oncology

P2.04-52 Impact of Corticosteroids and Antibiotics on Efficacy of Immune-Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer

(2019) M. Riudavets et al.   Journal of Thoracic Oncology

The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: a systematic review and meta-analysis of observational studies

(2019) Brooke E. Wilson et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer

(2018) L Derosa et al.   ANNALS OF ONCOLOGY

The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients

(2018) Vyara Matson et al.   SCIENCE

Tumor mutation burden (TMB) and immune-related adverse events (irAEs) compared to antibiotic (abx) use to predict for response to immune checkpoint inhibitors in esophagogastric cancer (EGC).

(2018) Megan Greally et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors

(2018) Jibran Ahmed et al.   OncoImmunology

Impact of antibiotic use on survival in patients with advanced cancers treated on immune checkpoint inhibitor phase I clinical trials

(2018) S Sen et al.   ANNALS OF ONCOLOGY

P1.07-008 Microbiome & Immunotherapy: Antibiotic Use Is Associated with Inferior Survival for Lung Cancer Patients Receiving PD-1 Inhibitors

(2017) J. Thompson et al.   Journal of Thoracic Oncology

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

(2017) V. Gopalakrishnan et al.   SCIENCE

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

(2017) Bertrand Routy et al.   SCIENCE

Mutations in DNA repair genes are associated with increased neo-antigen load and activated T cell infiltration in lung adenocarcinoma

(2017) Young Kwang Chae et al.   Oncotarget

Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma

(2016) Stefani Spranger et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy

(2015) A. Sivan et al.   SCIENCE

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

(2015) M. Vetizou et al.   SCIENCE

Role of the normal gut microbiota

(2015) Sai Manasa Jandhyala   WORLD JOURNAL OF GASTROENTEROLOGY

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

(2010) Andreas Stang   EUROPEAN JOURNAL OF EPIDEMIOLOGY

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE